These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21734806)

  • 1. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.
    Murata M; Furusyo N; Unno M; Ogawa E; Toyoda K; Taniai H; Ohnishi H; Hayashi J
    World J Gastroenterol; 2011 Jun; 17(24):2945-52. PubMed ID: 21734806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
    Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
    Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.
    Kirishima T; Okanoue T; Daimon Y; Itoh Y; Nakamura H; Morita A; Toyama T; Minami M
    J Hepatol; 2002 Aug; 37(2):259-65. PubMed ID: 12127432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T
    Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
    Akuta N; Suzuki F; Kobayashi M; Matsuda M; Sato J; Takagi K; Tsubota A; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY; Sabahi F; Amini-Bavil-Olyaee S; Alavian SM; Merat S
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
    Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
    J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
    Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
    Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
    J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.